Apigenin Protects Against Ischemic Stroke Through Anti- Inflammatory Mechanisms: A Study Combining Comprehensive Network Analysis, Mendelian Randomization and Animal Experiments for Validation.
APG can protect against IS by inhibiting the inflammatory response, providing a theoretical basis for clinical translation and further experimental research of APG.
Abstract
Background
AND
Objective
There is a well-established link between inflammation and Ischemic Stroke (IS) pathology. A natural compound, Apigenin (APG), has a neuroprotective effect. However, the specific mechanisms underlying the anti-inflammatory effects of APG and its protective effects on the blood-brain barrier following IS are unclear. This study aimed to explore the mechanisms behind the anti-inflammatory effect of APG in IS.
Methods
Male Sprague-Dawley rats were used to establish a model of unilateral middle cerebral artery occlusion (MCAO) and were administered APG by oral gavage at doses of 30, 60, or 120 mg/kg for 7 days. On the following day, brain tissues were collected after MCAO. Brain injury was evaluated by measuring brain water content, hematoxylin and eosin (H&E) staining, and Evans blue extravasation. To investigate potential proteins associated with inflammation, methods such as molecular docking, molecular dynamics simulations, Mendelian randomization analysis, immunohistochemistry, and Western blotting were employed.
Results
APG therapy has improved neurological deficiencies, lowered brain edema, and improved blood-brain barrier integrity. It has also resulted in decreased levels of inflammatory proteins TLR4, MyD88, NFκB, IL1β, MMP9, and iNOS after IS. Furthermore, IL1R2 was identified as a potential predictive target for IS.
Discussion
APG can repair nerve damage post-IS, with its protective effects mediated by anti-inflammatory mechanisms. The TLR4/myD88/NF-kB signaling pathway is a protective pathway of the body. APG may exert a protective effect on the blood-brain barrier after IS through the TLR4/MyD88/NF-kB signaling pathway.
Conclusion
APG can protect against IS by inhibiting the inflammatory response, providing a theoretical basis for clinical translation and further experimental research of APG.
Findings indicate that TZ may protect against CIRI by suppressing apoptosis and neuroinflammation through activation of the PI3K/AKT/mTOR signaling pathway, thereby providing preclinical evidence for its potential repurposing as a treatment for ischemic stroke.
Lin-Lin Xie, Yu-Kun Ping, Jie Zhao et al.· Current Neuropharmacology· 0 citations
ETHNOPHARMACOLOGICAL RELEVANCE
Houshiheisan (HSHS), a classical formula from the Synopsis of the Golden Chamber, is traditionally used for stroke and is known for its wind-dispelling and deficiency-tonifying properties. While HSHS has been confirmed to significantly reduce tissue necrosis following cerebral ischemia, i...
Yu-Xiang Wu, Xiao-Yao Guo, Ya-Wen Zhang et al.· Journal of Ethnopharmacology· 0 citations
The results demonstrated that eCBs and related lipid molecules significantly reduced cerebral infarct volume, improved neurological function score (NFS), and preserved blood–brain barrier (BBB) integrity, as evidenced by decreased BBB permeability and alleviated cerebral edema.
Xiao-Qun Li, Lu-Lu Wen, Yun Du et al.· European Journal of Medical...· 0 citations
Integrated transcriptomic and proteomic analyses suggest that Npy may be a key molecule in regulating IA progression and mediating MLT therapeutic effects, and its potential value is further supported by the immunohistochemical validation results.
Yan Liu, Hao-Yue Jiang, Yi-Fan Lu et al.· Drug Design, Development and...· 0 citations
From the current findings, curcumin has multiple therapeutic targets as an alternative to liraglutide and may possess the capacity to modulate neuroimmune dysfunction in diabetes by protecting the spleen–brain axis through JAK2/STAT3 modulation.
M. Khormi, Amal Naif Alshammari, R. A. Hegazy et al.· Pharmacognosy Magazine· 0 citations
Catechins represent promising candidate drugs for stroke due to their multiple neuroprotective potentials, but most preclinical evidence arises from pretreatment paradigms, which are confounded by heterogeneity in dosage, age, and experimental models.